An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Phase of Trial: Phase III
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Naquotinib (Primary) ; Erlotinib; Gefitinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLAR
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 31 Jan 2018 This trial was completed in Belgium (on 2017-12-21) according to european clinical trials database.
- 18 Jan 2018 This trial was completed in Hungary according to european clinical trials database.
- 04 Sep 2017 This trial has been suspended in Portugal.